Clinical Trials Logo

Detrusor Overactivity clinical trials

View clinical trials related to Detrusor Overactivity.

Filter by:

NCT ID: NCT05572918 Not yet recruiting - Overactive Bladder Clinical Trials

Developing a Simple Test to Diagnose Overactive Bladder

Start date: December 1, 2022
Phase:
Study type: Observational

In order to develop a test to diagnose overactive bladder from urine, it is essential that this test is at least as accurate as the tools that clinicians currently use. As such, this study will compare the performance of the device in development to the performance of existing methods.

NCT ID: NCT04978714 Completed - Clinical trials for Detrusor Overactivity

USI and/or DO in Women With Cystocele Before and After Cystocele Repair

Start date: November 1, 2010
Phase:
Study type: Observational

The changes of lower urinary tract function after cystocele repair are important for perioperative consultation and management. Thus, the aim of this retrospective study was to evaluate the prevalence of urodynamic stress incontinence and/or detrusor overactivity in women with ≥ stage II cystocele and the changes of incontinence function after cystocele repair.

NCT ID: NCT04693897 Not yet recruiting - Clinical trials for Overactive Bladder Syndrome

Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

Start date: March 1, 2021
Phase:
Study type: Observational [Patient Registry]

About one to two million women in Taiwan suffers from overactive bladder (OAB). The most commonly used anti-muscarinic drugs have a high rate of side effects. While beta-3 adrenoceptor agonist, Mirabegron, has far fewer side effects, there are no consensus on whether it can be used as first-line treatment. The investigator's preliminary study showed that the concentration of beta-3 adrenoceptor in the urine of OAB patients is higher than that in the normal control group, so comparing urinary beta-3 adrenoceptor concentration of OAB patients before and after treatment may be used as a biomarker of therapeutic effectiveness. The results of this study will be of great help in understanding the effectiveness of Mirabegron and formulating OAB treatment plans.

NCT ID: NCT04543552 Completed - Neurogenic Bladder Clinical Trials

A Comparative Analysis of Portable Bladder Scanner to Determine Age/ Volume Specific Accuracy in 0-6 Years of Children

Start date: November 13, 2017
Phase:
Study type: Observational

As a part of the urodynamic studies, urinary catheterization is inserted to measure residual urine, however, it has shown to be an invasive procedure, cause urinary tract infection, and traumatic experience. Bladder scan has been introduced as an alternative and non-invasive method to measure urine residual in the bladder.

NCT ID: NCT01850706 Completed - Clinical trials for Detrusor Overactivity

UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation

Start date: August 2011
Phase: N/A
Study type: Observational

The purpose of this study is to find a noninvasive test to help physicians diagnose detrusor overactivity (DO), to use this urine test to help diagnose bladder problems, determine if treatments are working, and determine if patients are good candidates for interventions like sacral neuromodulation/Interstim Therapy.

NCT ID: NCT01093534 Completed - Overactive Bladder Clinical Trials

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

SHRINK
Start date: January 2010
Phase: Phase 4
Study type: Interventional

The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.

NCT ID: NCT01023269 Terminated - Clinical trials for Urinary Incontinence

Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder

ACCEPTANCE
Start date: December 2009
Phase: N/A
Study type: Interventional

The study is designed to demonstrate that treatment with low level stimulation of the bladder muscles reduces symptoms of urinary incontinence in comparison with no stimulation.

NCT ID: NCT01003457 Completed - Clinical trials for Detrusor Overactivity

Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity

Start date: January 2005
Phase: N/A
Study type: Observational

In the last decade, several authors proposed ultrasound measurement of Bladder wall thickness (BWT) for the screening of the voiding dysfunction and of the detrusor overactivity (DO). The aims of the investigator prospective study were: - to compare the ultrasonographic measurement of BWT in women with DO vs women with other urodynamic diagnosis in a very large population. - to verify whether the BWT in women with DO can be different in the clinically or urodinamically different forms of DO.

NCT ID: NCT00822913 Enrolling by invitation - Parkinson's Disease Clinical Trials

Botulinum A Toxin in Patients With Parkinson's Disease

Botox-PD
Start date: June 2008
Phase: Phase 4
Study type: Interventional

The researchers investigated the effectiveness and safety of BoNT/A injected into the detrusor muscle in patients with PD and MSA all of whom had detrusor muscle overactivity unresponsive to conventional medical therapy.

NCT ID: NCT00678795 Completed - Multiple Sclerosis Clinical Trials

A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis

Start date: August 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in reducing the daily number of episodes on incontinence.